Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352 | 0.86 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL201 | 0.85 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL984922 | 0.85 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL16456600 | 0.85 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL11100306 | 0.85 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL276 | 0.82 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL653 | 0.82 | AGTR1 (0.62) | AGTR1AGTR2 | |
| SCHEMBL159 | 0.82 | AGTR1 (0.81) | AGTR1AGTR2 | |
| SCHEMBL3872329 | 0.81 | AGTR1 (0.59) | AGTR1AGTR2 | |
| SCHEMBL156 | 0.81 | AGTR1 (0.58) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | claimed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | claimed |
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | claimed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | claimed |
| EP-1885714-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK Pharmaceuticals D.D. (SI) | 2008-02-13 | — | — | EP | claimed |
| EP-1833801-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA, S.L (ES) | 2007-09-19 | — | — | EP | claimed |
| WO-2006125592-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS D.D. (SI) | 2006-11-30 | — | — | WO | claimed |
| WO-2006067215-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUÍMICA, S. L. (ES) | 2006-06-29 | — | — | WO | claimed |
| EP-1885714-B1 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS (SI) | 2014-01-15 | — | — | EP | disclosed |
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | LEK PHARMACEUTICALS, D.D. (SI) | 2009-07-09 | — | — | US | disclosed |
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | disclosed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | disclosed |
| EP-1885714-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK Pharmaceuticals D.D. (SI) | 2008-02-13 | — | — | EP | disclosed |
| EP-1833801-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA, S.L (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006125592-A2 | PROCESS FOR THE PREPARATION OF 2-ALKYL-1-((2'-SUBSTITUTED-BIPHENYL-4-YL)METHYL)-IMIDAZOLE, DIHYDROIMIDAZOLE OR BENZIMIDAZOLE DERIVATIVES | LEK PHARMACEUTICALS D.D. (SI) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006067215-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUÍMICA, S. L. (ES) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176849-A1 | Process for the preparation of 2-alkyl-1-((2'-substituted-biphenyl-4-yl) Methyl)-imidazole, dihydroimidazole or benzimidazloe derivatives | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.